Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
about
A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroupKey predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.
P2860
Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase 1 study of pazopanib alo ...... se patients with solid tumors.
@ast
Phase 1 study of pazopanib alo ...... se patients with solid tumors.
@en
type
label
Phase 1 study of pazopanib alo ...... se patients with solid tumors.
@ast
Phase 1 study of pazopanib alo ...... se patients with solid tumors.
@en
prefLabel
Phase 1 study of pazopanib alo ...... se patients with solid tumors.
@ast
Phase 1 study of pazopanib alo ...... se patients with solid tumors.
@en
P2093
P2860
P1476
Phase 1 study of pazopanib alo ...... ese patients with solid tumors
@en
P2093
Akiko Takekura
Ayako Mitsuma
Fumio Nagashima
Hiroo Ishida
Kazuo Nagamatsu
Keiko Mizuno
Keishi Yamashita
Kenji Kawada
Masataka Sawaki
Megumi Inada-Inoue
P2860
P2888
P304
P356
10.1007/S00280-014-2374-3
P577
2014-01-24T00:00:00Z
P5875
P6179
1022673091